Results 31 to 40 of about 29,513 (309)

Chronic Hepatitis C Treatment with New Antiviral Agents

Mediterranean Journal of Infection, Microbes and Antimicrobials, 2018
Recent advances in our knowledge of hepatitis C virus (HCV) molecular biology have enabled improvements in the efficacy and tolerability of HCV treatment, and in this regard many direct-acting antiviral (DAA) agents have been developed.
Özlem KANDEMİR
doaj   +1 more source

Prevalence of resistance-associated substitutions and phylogenetic analysis of hepatitis C virus infection in Russia

International Journal of Infectious Diseases, 2021
Objectives: Due to limited hepatitis C virus (HCV) sequence availability from patients in Russia, the relationship between subtypes and baseline resistance-associated substitutions (RAS) to direct antiretroviral treatment outcome is not fully understood.
Vasily Isakov, Charlotte Hedskog, Joel O. Wertheim, Reilly E. Hostager, Bandita Parhy, Adriano De Bernardi Schneider, Vithika Suri, Hongmei Mo, Natalia Geivandova, Vyacheslav Morozov, Elena Bessonova, Natalya Gankina, Konstantin Zhdanov, Dzhamal Abdurakhmanov, Evguenia Svarovskaia   +14 more
doaj   +1 more source

Clinician barriers, perceptions, and practices in treating patients with hepatitis C virus and substance use disorder in the United States

Preventive Medicine Reports, 2023
The likelihood of clinicians prescribing direct-acting antiviral (DAA) therapy for patients with chronic hepatitis C virus (HCV) and substance use disorder (SUD) was assessed via a survey emailed throughout the United States to clinicians (physicians and
Haesuk Park, Carolyn Brown, Debbie L. Wilson, Pei-Lin Huang, Pilar Hernández-Con, Patrick Horne, Amie Goodin, Amanda Joseph, Rich Segal, Roniel Cabrera, Robert L. Cook   +10 more
doaj   +1 more source

Mechanisms of Hepatitis C Viral Resistance to Direct Acting Antivirals

Viruses, 2015
There has been a remarkable transformation in the treatment of chronic hepatitis C in recent years with the development of direct acting antiviral agents targeting virus encoded proteins important for viral replication including NS3/4A, NS5A and NS5B ...
Asma Ahmed, Daniel J. Felmlee
doaj   +1 more source

Variable short duration treatment versus standard treatment, with and without adjunctive ribavirin, for chronic hepatitis C: the STOP-HCV-1 non-inferiority, factorial RCT

Efficacy and Mechanism Evaluation, 2021
Background: High cure rates with licensed durations of therapy for chronic hepatitis C virus suggest that many patients are overtreated. New strategies in individuals who find it challenging to adhere to standard treatment courses could significantly ...
Graham S Cooke, Sarah Pett, Leanne McCabe, Christopher Jones, Richard Gilson, Sumita Verma, Stephen D Ryder, Jane D Collier, Stephen T Barclay, Aftab Ala, Sanjay Bhagani, Mark Nelson, Chin Lye Ch’Ng, Benjamin Stone, Martin Wiselka, Daniel Forton, Stuart McPherson, Rachel Halford, Dung Nguyen, David Smith, M Azim Ansari, Helen Ainscough, Emily Dennis, Fleur Hudson, Eleanor J Barnes, Ann Sarah Walker, the STOP-HCV trial team   +26 more
doaj   +1 more source

Clinical-evolutional particularities of the cryoglobulinemic vasculitis in the case of a patient diagnosed with hepatitis C virus in the predialitic phase [PDF]

, 2018
Hepatitis C virus (HCV) represents a fundamental issue for public health, with long term evolution and the gradual appearance of several complications and associated pathologies.
Boldeanu, Lidia, Boldeanu, Mihail V., Caragea, Daniel C., Ciurea, Marius E., Ciurea, Tudorel, Forțofoiu, Maria, Forțofoiu, Mircea C., Popescu-Drigă, Mircea, Pădureanu, Vlad, Rogoveanu, Ion, Streba, Costin, Săndulescu, Larisa, Vere, Cristin C.   +12 more
core   +3 more sources

Hepatitis C virus cell-cell transmission and resistance to direct-acting antiviral agents [PDF]

, 2014
Hepatitis C virus (HCV) is transmitted between hepatocytes via classical cell entry but also uses direct cell-cell transfer to infect neighboring hepatocytes.
A Owsianka, A Sigal, Aleem Siddiqui, Arvind H. Patel, AS Lok, AW Tarr, B Bartolini, B Sainz Jr, C Hezode, C Lee, C Nathan, C Sarrazin, CL Brimacombe, CM Lange, CT Jones, D Masson, D Trono, EJ Gane, Eric Soulier, F Kuonen, F Poordad, F Poordad, Fei Xiao, François Habersetzer, G Koutsoudakis, H Kwon, H Yan, H Zhu, Heidi Barth, I Fofana, I Fofana, I Fofana, IA Abela, IM Jacobson, Isabel Fofana, J Grove, J Lupberger, J Witteveldt, J Zhong, Jens Bukh, JG McHutchison, JM Gottwein, JM Gottwein, JM Pawlotsky, JM Pawlotsky, JM Pawlotsky, JM Timpe, L Rong, L Zona, Laura Heydmann, LW Meredith, MB Zeisel, MB Zeisel, Michel Doffoël, Mirjam B. Zeisel, MN Zahid, MS Sulkowski, MT Catanese, N Shi, O Lenz, P Zhong, PM Trembling, Q Sattentau, S Haid, T Pietschmann, T Pietschmann, T Wakita, Thomas F. Baumert, TJ Liang, TK Scheel, V Soriano, VD Cataldo, ZY Keck   +72 more
core   +7 more sources

Update on hepatitis C: Direct-acting antivirals

World Journal of Hepatology, 2015
Hepatitis C virus (HCV) was discovered 26 years ago. For decades, interferon-based therapy has been the mainstay of treatment for HCV. Recently, several direct-acting antivirals (DAAs) have been approved for treatment of HCV-infected patients and to help combat the virus.
Leon L, Seifert, Ryan B, Perumpail, Aijaz, Ahmed   +2 more
openaire   +2 more sources

Sofosbuvir-based antiviral therapy in patients with recurrent HCV infection after liver transplant: A real-life experience

Annals of Hepatology, 2019
Introduction and aim: Recurrent HCV infection after liver transplant (LT) has a negative impact on graft and patient survival. The aim of this study is to describe the efficacy and safety of sofosbuvir (SOF-based) regimens in the treatment of recurrent ...
Alexandre Araujo, Vanessa Valenzuela-Granados, Antonio B. Lopes, Matheus T. Michalczuk, Augusto Mantovani, Mario R. Alvares-da-Silva   +5 more
doaj   +1 more source

Efficacy of direct-acting antivirals in patients with hepatitis C virus-associated cryoglobulinemic vasculitis: Results of a long-term follow-up

Научно-практическая ревматология, 2023
Objective – to evaluate the long-term outcomes of HCV eradication with direct-acting antivirals (DAAs) in patients with hepatitis C-associated cryoglobulinemic vasculitis (HCV-CV)Materials and methods.
S. V. Gavrisheva, D. T. Abdurakhmanov, N. M. Bulanov, E. L. Tanashhuk, T. P. Rozina, E. N. Nikulkina, S. Yu. Milovanova, E. A. Nabatchikova, A. L. Filatova, E. E. Starostina, T. N. Krasnova, S. V. Moiseev   +11 more
doaj   +1 more source